Incyclix Bio

Incyclix Bio, LLC is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound is a potent and selective cyclin-dependent kinase 2 inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers.

Additional Details

Company Size:

1-9 Employees